Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

doi:10.1038/nrc2947

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Nature reviews. Cancer - 1 Nov 2010

Pao William, Chmielecki Juliann

Abstract excerpt

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have...

Topics

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
ErbB Receptors
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 20966921
DOI: 10.1038/nrc2947
PMCID: PMC3072803

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics